The Q4 2026 MAD data readouts for SRP-1003 (DM1) and SRP-1001 (FSHD) are the next major catalysts; positive results could support Phase 3 advancement and re-rate the stock. The raised revenue guidance and narrowed expense range signal improved operational visibility, but ELEVIDYS revenue remains pressured by the ambulatory-only label.
Drugs in focus
SRPT drug pipeline →AMONDYS 45
◆ Mixed Named in this 8-K- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already on the market under accelerated approval (since February 2021). The sNDA for traditional approval has a PDUFA goal date around April 2027.
- Next catalyst
- None dated
What to watchWatch for the FDA's decision on the sNDA for traditional approval of AMONDYS 45, expected around April 2027 (standard review timeline from the June 30, 2026 acceptance). Approval would remove the overhang from the failed ESSENCE confirmatory trial and solidify the PMO franchise's revenue stream. Denial could threaten the drug's continued marketing and would be a significant negative for SRPT shares.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $17.82entry
- T+1 · 8d ago −3.25%α −5.62% · $17.24
- T+5 · 4d ago −9.82%α −12.42% · $16.07
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
The company raised the low end of full-year net product revenue guidance by $50M to $1.25B-$1.3B and lowered the high end of expense guidance by $25M to $800M-$825M, driven by strong PMO franchise performance and operating discipline. Upcoming multiple ascending dose data for SRP-1003 (DM1) and SRP-1001 (FSHD) by year-end are key pipeline catalysts.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $381.4M, down 5% YoY from $399.4M
- Net product revenue $323.8M: PMO $240.3M, ELEVIDYS $83.5M
- Full-year 2026 net product revenue guidance raised to $1.25B-$1.3B (low end +$50M)
- Full-year combined non-GAAP R&D and SG&A expense guidance narrowed to $800M-$825M (high end -$25M)
- Cash, cash equivalents, restricted cash and investments $998.7M at Sep 30, 2026
- MAD data for SRP-1003 (DM1) and SRP-1001 (FSHD) expected Q4 2026
Financial Impact
Revenue declined $18M YoY; GAAP operating loss improved $94.4M to $9.0M loss; guidance raised by $50M at low end
Risk Factors
- ELEVIDYS revenue continues to decline due to label restriction to ambulatory patients
- Take-or-pay charge of $62M related to Catalent manufacturing obligations
- Upcoming DM1/FSHD data may not support advancement to Phase 3
- Litigation settlement charge of $39M recorded in Q2 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-449822 |
| Document: srpt-20261105.htm | 0001193125-26-449822 |
| Document: 0001193125-26-449822-index-headers.html | 0001193125-26-449822 |
| Document: 0001193125-26-449822-index.html | 0001193125-26-449822 |
| Document: 0001193125-26-449822.txt | 0001193125-26-449822 |
| 8-K Data (Synthetic) | 0001193125-26-449822 |
Track record
9 reports on SRPT
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $16.07 Now $15.13 −5.85% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.42 Now $15.13 −7.86% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $17.82 Now $15.13 −15.10% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $18.54 Now $15.13 −18.39% settles Dec 2
- Jul 27, 202616w ago 8-K Neutral 3/10 Entry $15.89 to $18.13 Now $15.13 −4.78% ▲ +14.10% +10.80% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $15.00 to $20.52 Now $15.13 +0.87% ▲ +36.80% +34.91% vs SPY
- Jun 4, 202623w ago 8-K Neutral 3/10 Entry $15.75 to $19.18 Now $15.13 −3.94% ▲ +21.78% +19.92% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $20.89 to $16.67 Now $15.13 −27.56% ▼ −20.18% −25.14% vs SPY
- Feb 25, 202637w ago 8-K Mixed 7/10 Entry $17.45 to $21.68 Now $15.13 −13.30% ▲ +24.24% +30.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers